Meeting
2011 ASCO Annual Meeting
Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies
Authors
C. A. Ramos
Baylor College of Medicine, Houston, TX
C. A. Ramos , B. Savoldo , E. Liu , C. M. Bollard , M. P. Mims , M. J. Keating , A. P. Gee , Z. Mei , C. M. Rooney , H. E. Heslop , M. K. Brenner , G. Dotti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT00586391
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2541)
Abstract #
2541
Poster Bd #
1B
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells.
First Author: Aaron E Foster
Poster
2020 ASCO Virtual Scientific Program
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
First Author: Hong-jiu Dai
Poster
2016 ASCO Annual Meeting
A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma.
First Author: Sarah Nikiforow
Poster
2016 Genitourinary Cancers Symposium
Inducible MyD88/CD40 to allow rimiducid-dependent activation for control of proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA).
First Author: Kevin Mark Slawin